Merck's $10.8 Billion Bet on Prometheus Yields Mid-Stage Breakthrough

Merck has announced positive mid-stage results for its Prometheus drug in a painful skin disease. The company detailed some of this data on Wednesday morning, which is part of the $10.8 billion acquisition of Prometheus BioSciences.

The results showed significant improvement in symptoms for patients with the debilitating skin condition. Merck did not specify the exact number of patients involved in the study or provide further details about the treatment's efficacy and safety profile.

This is a major development for Merck, which has been expanding its pipeline through strategic acquisitions like the Prometheus deal. The company will likely continue to monitor the progress of this drug as it moves forward in clinical trials.